ARCH Venture Partners X, LLC's Net Worth
$629 Million
Who is ARCH Venture Partners X, LLC?
ARCH Venture Partners X, LLC has an estimated net worth of $629 Million. This is based on reported shares across multiple companies, which include Sana Biotechnology, Inc., Neumora Therapeutics, Inc., Erasca, Inc., Verve Therapeutics, Inc., Sienna Biopharmaceuticals, Inc., and Prime Medicine, Inc..
SEC CIK
ARCH Venture Partners X, LLC's CIK is 0001769012
Past Insider Trading and Trends
2023 was ARCH Venture Partners X, LLC's most active year for acquiring shares with 12 total transactions. ARCH Venture Partners X, LLC's most active month to acquire stocks was the month of August. 2021 was ARCH Venture Partners X, LLC's most active year for disposing of shares, totalling 20 transactions. ARCH Venture Partners X, LLC's most active month to dispose stocks was the month of January. 2023 saw ARCH Venture Partners X, LLC paying a total of $51,000,000.00 for 37,849,408 shares, this is the most they've acquired in one year. In 2022 ARCH Venture Partners X, LLC cashed out on 35,616,279 shares for a total of $0.00, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Neumora Therapeutics, Inc. (NMRA) Snapshot price: $16.96
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +102.76% | 1.88M |
—
|
—
| 3.71M |
Dec 8
| |||
Form 4
| +178.19% | 18.92M |
$17.00 |
—
| 29.55M |
Sep 19
| |||
Form 4
| +178.19% | 18.92M |
$17.00 |
—
| 29.55M |
Sep 19
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Erasca, Inc. (ERAS) Snapshot price: $1.705
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
∞
| 11.06M |
—
|
—
| 11.06M |
Jul 20
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Verve Therapeutics, Inc. (VERV) Snapshot price: $10.97
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
∞
| 2.51M |
—
|
—
| 2.51M |
Jun 21
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Sienna Biopharmaceuticals, Inc. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +59.61% | 2.17M |
$2.50 | $5,414,500.00 | 5.8M |
Feb 22
| |||
| No matching records found | |||||||||
Prime Medicine, Inc. (PRME) Snapshot price: $6.51
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
∞
| 3.2M |
$6.25 | $20,000,000.00 | 3.2M |
Feb 15
| |||
Form 4
|
∞
| 12.26M |
$17.00 |
—
| 12.26M |
Oct 24
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||